Methods of treating conditions with a metal-containing material

• US 7,470,437 B2
• Filed: 11/10/2004
• Issued: 12/30/2008
• Est. Priority Date: 07/27/2000
• Status: Expired due to Term

• Current Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Original Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Inventors: Gillis, Scott H., Schechter, Paul, Naylor, Antony G., Lam, Kan, Wright, John B., Burrell, Robert E., Moxham, Peter H.
• Primary Examiner(s): PAK, JOHN D
• Application Number:
  US10/985,204
• Publication Number:
  US 20050129624A1
• Time in Patent Office: 1,511 Days
• Field of Search: 424/618, 424/619, 424/489
• US Class Current: 424/618
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 2800/413 Nanosized, i.e. having sizes below 100 nm
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/242 Gold; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 33/38 Silver; Compounds thereof
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 8/19 containing inorganic ingredients
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/1682 Processes
• CPC Class Codes: A61K 9/51 Nanocapsules; Nanoparticles; nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61K 9/7023 : Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61L 15/44 : Medicaments
• CPC Class Codes: A61L 15/46 : Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
• CPC Class Codes: A61L 17/145 : Coating
• CPC Class Codes: A61L 2300/102 : Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
• CPC Class Codes: A61L 2300/104 : Silver, e.g. silver sulfadiazine
• CPC Class Codes: A61L 2300/404 : Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/606 : Coatings
• CPC Class Codes: A61L 2300/624 : Nanocapsules
• CPC Class Codes: A61L 2300/63 : Crystals
• CPC Class Codes: A61L 27/30 : Inorganic materials
• CPC Class Codes: A61L 27/54 : Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 29/10 : Inorganic materials
• CPC Class Codes: A61L 29/16 : Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/082 : Inorganic materials
• CPC Class Codes: A61L 31/16 : Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 1/00 : Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61Q 17/005 : Antimicrobial preparations
• CPC Class Codes: A61Q 19/00 : Preparations for care of the skin
• CPC Class Codes: B82Y 5/00 : Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Methods of treating conditions with a metal-containing material are disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.

Claims

1. A method of treating a subject having a condition, comprising:

contacting an inflamed or infected problem area of a mucosal membrane of the subject having the condition with a nanocrystalline silver-containing compound to provide a localized anti-inflammatory effect, the silver-containing compound is characterized by sufficient atomic disorder so that the silver-containing compound, in contact with an alcohol or water-based electrolyte, releases atoms, ions, molecules, or clusters of the silver-containing compound on a sustainable basis and at a concentration sufficient to provide a localized anti-inflammatory effect or antimicrobial effect,

wherein the condition is mucositis or stomatitis.

2. The method of claim 1, wherein the nanocrystalline silver-containing compound is further selected from the group consisting of silver oxides, silver nitrides, silver borides, silver halides, silver hydrides.

3. The method of claim 1, wherein the nanocrystalline silver-containing compound comprises an antimicrobial compound.

4. The method of claim 1, wherein, when contacted with the area of the subject having the condition, the nanocrystalline silver-containing compound is in a solution.

5. The method of claim 4, wherein the solution is injected.

6. The method of claim 5, wherein the solution is injected via a needleless injector.

7. The method of claim 5, wherein the solution is injected via a needle.

8. The method of claim 4, wherein the solution contains at least about 0.001 weight percent of the nanocrystalline silver-containing compound.

9. The method of claim 8, wherein the solution contains about 10 weight percent or less of the nanocrystalline silver-containing compound.

10. The method of claim 4, wherein the solution further comprises a solvent.

11. The method of claim 1, wherein, when contacted with the area of the subject having the condition, the nanocrystalline silver-containing compound is disposed in a pharmaceutically acceptable carrier.

12. The method of claim 11, wherein the composition contains at least about 0.01 weight percent of the nanocrystalline silver-containing compound.

13. The method of claim 12, wherein the composition contains about 50 weight percent or less of the nanocrystalline silver-containing compound.

14. The method of claim 11, wherein the pharmaceutically acceptable carrier is selected from the group consisting of creams, ointments, gels, lotions, pastes and foams.

15. The method of claim 1, wherein, when contacted with the area of the subject having the condition, the nanocrystalline silver-containing compound is in the form of a free-standing powder.

16. The method of claim 15, wherein the free-standing powder is injected.

17. The method of claim 1, wherein the condition is mucositis.

18. The method of claim 1, wherein the condition is stomatitis.

19. The method of claim 4, wherein the solution is contacted with the problem area as a rinse, wash, gargle, or drop.

20. The method of claim 1, wherein, when contacted with the subject having the condition, the nanocrystalline silver-containing compound is in a tape, pill, capsule, tablet, or lozenge.